Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Equity (2018 - 2025)

Historic Return on Equity for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 0.07%.

  • Protagonist Therapeutics' Return on Equity fell 2500.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of 0.54% for FY2024, which is 8300.0% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Return on Equity stood at 0.07% for Q3 2025, which was down 2500.0% from 0.08% recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Return on Equity ranged from a high of 0.46% in Q4 2024 and a low of 0.65% during Q1 2023
  • Over the past 5 years, Protagonist Therapeutics' median Return on Equity value was 0.28% (recorded in 2021), while the average stood at 0.18%.
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 10100bps in 2024, then crashed by -2800bps in 2025.
  • Over the past 5 years, Protagonist Therapeutics' Return on Equity (Quarter) stood at 0.4% in 2021, then tumbled by -39bps to 0.55% in 2022, then skyrocketed by 55bps to 0.25% in 2023, then skyrocketed by 284bps to 0.46% in 2024, then tumbled by -85bps to 0.07% in 2025.
  • Its Return on Equity was 0.07% in Q3 2025, compared to 0.08% in Q2 2025 and 0.08% in Q1 2025.